Courier | treatment last year! Phase 2 trials of oral JAK inhibitors were positive and effective in treating this type of skin disease

2023-02-15

Incyte has released the results of a new 52-week trial evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS). The results showed that the status of the abscess and inflammatory nod

Key frontier | found knee pain treatment! STAT3 makes chondrocytes young again

2023-01-30

Many of us wake up stiff in the morning and find it difficult to move, or we often experience knee pain and difficulty walking up and down stairs. These symptoms we think of as signs of "getting old" are actually a medical condition called osteoarthritis

Courier | significantly lower blood sugar level, diabetes therapy phase 3 of the primary end point

2022-12-12

Eli Lilly and Boehringer Ingelheim recently presented the results of Phase 3 clinical trials at the International Diabetes Federation (IDF) World Diabetes Congress 2022. Its partner drug, Jardiance, is the first SGLT2 inhibitor to be shown to produce a st

SGLT-2 inhibitors: from hypoglycemic to improved cardiac, cerebral and renal clinical outcomes

2022-12-07

Courier | significantly slow kidney disease progression and cardiovascular death! The blockbuster SGLT2 inhibitor reached phase 3 clinical endpoint

2022-11-07

Today, Boehringer Ingelheim and Eli Lilly and Company announced that Jardiance (empagliflozin) met its primary endpoint in a Phase 3 clinical trial, This drug significantly reduces the risk of kidney disease progression or cardiovascular death in adult

Courier | targeted STAT3 treatment of hepatocellular carcinoma (HCC), innovative therapy for the FDA to fast-track qualification​

2022-10-31

Tvardi Therapeutics (TVARDI) recently announced that TTI-101, an oral small-molecule STAT3 inhibitor, has received fast-track FDA status for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma (H

Phase 3 clinical success of new drugs for diabetes mellitus

2022-10-26

Lexicon Pharmaceuticals, a wuxi Apptec partner, reported positive data from its phase 3 inTandem1 study. Previously, the company announced that both doses of sotagliflozin met the primary end point of the inTandem1 study, with data showing a statistically

The second imported compound antidiabetic drug is coming in 2017

2022-10-26

CFDA approved the marketing of dalatavir hydrochloride tablets and asurevir soft capsules

2022-10-26

News | inflammatory spinal disease treatment, Abbvie JAK inhibitor in two phase 3 clinical test the primary end point

2022-10-26